Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COR-1167 in Worsening Heart Failure
NCT06815471Phase 2Suspended
- Sponsor
- Corteria Pharmaceuticals
- Start
- Aug 2025
- Primary completion
- Dec 2026
- Modality
- Peptides, Small Molecules
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial of COR-1167 in heart failure (HF) (4 arms), sponsored by Corteria Pharmaceuticals. Primary endpoints: Natriuresis at 24 hours, Body weight at 7 days and 3 more. Started Aug 2025; status: suspended.
02
Drugs
COR-1167
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT06815471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06815471.